Does Low Vitamin D Make Post-Surgery Pain Worse? What a New Mastectomy Study Shows

A 2026 prospective observational study of 184 breast cancer patients found that vitamin D deficiency — defined as a serum 25(OH)D level below 30 nmol/L — was independently associated with a threefold greater likelihood of moderate to severe postoperative pain in the first 24 hours after radical mastectomy, along with substantially higher opioid consumption compared to patients with sufficient vitamin D levels.

The research, published in Regional Anesthesia & Pain Medicine and conducted at Fayoum University Hospital in Egypt between September 2024 and April 2025, adds meaningful weight to a growing body of evidence suggesting that vitamin D does more than protect bones — it may actively shape how the body experiences and processes pain after major surgery.

At a Glance: Vitamin D-Deficient vs. Vitamin D-Sufficient Mastectomy Patients

The table below summarises the key clinical differences between the two groups in the study, drawn directly from the published findings:

Outcome Measure	Vitamin D-Deficient Group (<30 nmol/L)	Vitamin D-Sufficient Group (≥30 nmol/L)	Clinical Significance
Average patient age	44 years	42 years	Groups broadly comparable
Moderate-to-severe pain (NRS >3) in first 24 hrs	~3× more likely	Reference group	Adjusted OR 3.12 (95% CI 1.58–6.13)
Intraoperative fentanyl use	~8 µg more (mean diff 8.04 µg)	Reference group	Modest but statistically significant
Postoperative tramadol use	~112 mg more (mean diff 112.17 mg)	Reference group	Clinically substantial difference
Postoperative nausea	More frequent	Less frequent	Consistent with higher opioid load
Vomiting	Occurred only in deficient group	Not reported	Difference not statistically significant
Severe pain (NRS ≥7)	Not reported in either group	Not reported in either group	Pain difference confined to moderate range (NRS 4–6)

Sources: PubMed abstract, BMJ Group press release

---

What exactly did the study do, and why does the design matter?

A prospective observational study enrolls participants before the outcome of interest occurs and follows them forward in time, without assigning them to different treatments. That distinction matters here because the researchers tracked real-world clinical outcomes rather than testing an intervention — which limits what conclusions can be drawn, but also means the findings reflect genuine clinical practice rather than an artificial trial setting.

The Fayoum University Hospital study enrolled 184 female breast cancer patients classified as American Society of Anesthesiologists (ASA) grade II–III who were scheduled for elective unilateral modified radical mastectomy — a procedure in which an entire breast, along with surrounding lymph nodes, is surgically removed. Patients were divided evenly into two groups of 92: those with preoperative serum 25(OH)D below 30 nmol/L (deficient) and those at or above 30 nmol/L (sufficient).

Crucially, the clinical staff caring for patients were blinded to vitamin D status throughout the study. This blinding reduces the risk that treatment decisions — such as how much pain medication to offer — were unconsciously influenced by knowledge of a patient's vitamin D level. All patients received the same standard protocol: fentanyl during surgery for acute pain management, followed by intravenous paracetamol every eight hours post-operatively. Additional tramadol was available via a patient-controlled analgesia (PCA) button, capped at 50 mg per hour, allowing researchers to objectively measure how much extra opioid each patient actually chose to take.

Pain was recorded using the Numerical Rating Scale (NRS, 0–10) immediately after surgery and again at 6, 12, 18, and 24 hours. The primary outcome was moderate-to-severe pain (NRS >3) at 12 hours; a secondary composite outcome tracked NRS >3 at any point in the first 24 hours and was used for multivariable logistic regression.

What were the actual pain findings?

The headline result is striking: vitamin D deficiency was independently associated with moderate-to-severe postoperative pain at any time point during the first 24 hours, with an adjusted odds ratio of 3.12 (95% CI 1.58 to 6.13). A deficient patient was roughly three times more likely to report pain in the moderate range (NRS 4–6) at some point during their first day of recovery.

One detail worth noting: no patient in either group reported severe pain (NRS ≥7). The entire difference between the groups was driven by a higher proportion of deficient patients experiencing moderate pain — not extreme agony, but the kind of persistent, uncomfortable pain that disrupts sleep, impairs mobility, and motivates patients to press the opioid button more often.

Pain scores were recorded at multiple time points, and the difference between groups was consistent across the measurement window rather than spiking at a single moment. This temporal consistency strengthens the association, even if it cannot establish causation.

How much more opioid medication did deficient patients use?

The opioid consumption data is where the practical clinical implications become clearest. Vitamin D-deficient patients received an average of 8.04 µg more fentanyl intraoperatively (95% CI 3.21 to 12.88 µg) — a modest difference, though fentanyl is a potent synthetic opioid, so even modest increases in dosing carry some clinical relevance.

The post-operative tramadol gap was far larger. Deficient patients used an average of 112.17 mg more tramadol than sufficient patients (95% CI 101.44 to 122.91 mg) — a difference that is both statistically solid and clinically meaningful. Tramadol is a centrally acting opioid analgesic; at higher cumulative doses, it is associated with nausea, vomiting, sedation, and in vulnerable patients, risks of dependence and serotonin-related side effects.

The fact that patients controlled their own tramadol dosing via a PCA device is an important methodological strength. It means the difference in consumption reflects the patients' own subjective experience of pain rather than a clinician's decision about how much medication to prescribe.

Consistent with higher opioid use, postoperative nausea was more common in the vitamin D-deficient group. Vomiting was reported only in the deficient group, though the difference did not reach statistical significance — meaning researchers could not confidently rule out chance as an explanation for that particular finding.

Why might vitamin D affect pain sensitivity?

Vitamin D is a fat-soluble secosteroid hormone that the body synthesises primarily through ultraviolet-B exposure of the skin, with dietary intake and supplementation as secondary sources. Its classical role is in calcium and phosphorus metabolism and bone mineralisation, but research over the past two decades has identified vitamin D receptors in neural tissue, immune cells, and muscle — pointing to a much broader biological footprint.

The proposed mechanisms linking vitamin D to pain modulation are not yet fully established, but several pathways are plausible. Vitamin D appears to regulate the expression of pro-inflammatory cytokines, including interleukin-6 and tumour necrosis factor-alpha, both of which can sensitise peripheral nociceptors and lower the pain threshold. It also influences prostaglandin synthesis and may modulate central sensitisation through effects on glial cells in the spinal cord.

In the context of surgery, where tissue injury triggers a cascade of inflammatory signalling, a patient with already-depleted vitamin D reserves may be less equipped to dampen that inflammatory response — leaving pain-sensing pathways more activated than they would be in a vitamin D-sufficient patient.

The Fayoum study did not measure inflammatory markers, so this mechanistic explanation remains speculative for this particular dataset. The researchers acknowledged this as a limitation and called for future studies to investigate the biological pathways involved.

Why are breast cancer patients particularly at risk of vitamin D deficiency?

Vitamin D deficiency — generally defined as a serum 25-hydroxyvitamin D concentration below 30 nmol/L (12 ng/mL), though some organisations set the threshold higher at 50 nmol/L — is common in the general population and appears to be disproportionately prevalent among people with breast cancer.

Several factors may contribute. Breast cancer patients often reduce sun exposure due to fatigue, hospitalisation, or concerns about skin damage from radiation therapy. Chemotherapy and other systemic treatments can affect vitamin D metabolism. Obesity, a risk factor for breast cancer, is also associated with lower circulating vitamin D because the fat-soluble vitamin is sequestered in adipose tissue. Older age, darker skin pigmentation, and geographic latitude all further reduce baseline vitamin D status.

The study's Egyptian setting is worth noting. Despite Egypt's abundant sunlight, vitamin D deficiency is paradoxically common in the region, partly due to cultural practices involving covered clothing and limited outdoor activity, particularly among women. The 50% deficiency rate observed in the study cohort — while striking — is consistent with broader epidemiological patterns in the region.

What are the study's limitations, and how much weight should these findings carry?

The researchers were transparent about the study's constraints, and they are worth examining carefully before drawing clinical conclusions.

Because the study is observational rather than a randomised controlled trial, it cannot establish that low vitamin D directly caused higher pain or greater opioid use. Unmeasured confounding variables — factors that correlate with both vitamin D status and pain outcomes — could explain part or all of the association. The researchers controlled for several variables in their multivariable analysis, which produced the adjusted OR of 3.12, but residual confounding cannot be ruled out.

The study was also conducted at a single centre in Egypt. Patient populations, surgical techniques, anaesthetic protocols, and post-operative care practices vary across institutions and countries, so the findings need replication in diverse settings before broad clinical recommendations can be made. Several factors known to influence post-operative pain were not collected: pre-operative anxiety and depression, cancer stage and prior treatment history, and pre-surgical sleep disturbance. Any of these could plausibly differ between vitamin D-deficient and sufficient patients and independently affect pain outcomes. Inflammatory markers were not measured either, leaving the proposed biological mechanism untested in this dataset.

Despite these limitations, the study's strengths — prospective design, blinded clinical staff, objective opioid consumption data via PCA, and a well-balanced comparison between groups — give the findings credibility as a signal worth pursuing in larger, randomised trials.

What do the researchers recommend, and is supplementation safe?

The study authors stop short of issuing a clinical directive, but their conclusion is pointed: "Preoperative vitamin D supplementation in breast cancer patients with vitamin D levels below 30 nmol/L may have a role in modulating postoperative pain," they write.

This is a hypothesis-generating recommendation rather than a practice-changing guideline. The study does not test supplementation — it only observes the association between baseline vitamin D status and pain outcomes. To know whether correcting deficiency before surgery actually reduces post-operative pain, a randomised trial would need to assign deficient patients to either vitamin D supplementation or placebo before surgery and compare outcomes.

That said, vitamin D supplementation at doses used to correct deficiency (typically 1,000–4,000 IU daily for several weeks) carries a well-established safety profile and is inexpensive. The risk-benefit calculus for pre-operative supplementation in deficient breast cancer patients is therefore relatively favourable, even in the absence of definitive trial evidence — though this is a decision that should involve the patient's oncology and anaesthesia teams.

How does this study fit into the broader picture of vitamin D and pain research?

The Fayoum mastectomy study is not the first to link vitamin D status to pain sensitivity, but it is notable for its focus on acute surgical pain in a specific, high-stakes clinical context. Earlier research has associated vitamin D deficiency with chronic musculoskeletal pain, fibromyalgia, and lower back pain, and some small trials have found that supplementation reduces pain scores in these conditions. The American Dental Association has also noted the emerging relevance of vitamin D status for predicting postoperative pain, suggesting the relationship may extend across different types of surgical and procedural pain.

The mastectomy context is particularly important because of the opioid dimension. Breast cancer surgery already carries a significant risk of acute and chronic post-operative pain, and opioid use in the peri-operative period contributes to side effects that slow recovery, extend hospital stays, and — in some patients — can initiate or worsen opioid dependence. A simple, low-cost nutritional intervention like pre-operative vitamin D supplementation that could meaningfully reduce opioid consumption after mastectomy would carry substantial public health implications.

The finding that deficient patients used 112 mg more tramadol on average is not a trivial number. At a maximum dose of 50 mg per hour via PCA, that represents more than two additional hours of maximum-rate opioid self-administration in the first 24 hours alone. Multiplied across the hundreds of thousands of mastectomies performed globally each year, the aggregate opioid burden associated with vitamin D deficiency could be considerable.

What should patients and clinicians take away from this research?

For breast cancer patients preparing for mastectomy, this study raises a reasonable question worth discussing with their surgical and anaesthesia teams: has their vitamin D status been checked, and if deficient, is there time to address it before surgery?

Pre-operative nutritional optimisation is already a component of enhanced recovery after surgery (ERAS) protocols in many centres, though vitamin D is not yet a standard part of most pre-operative screening panels. The Fayoum findings provide a concrete, quantified rationale for including it — at least in patient populations where deficiency is common.

For clinicians, the study reinforces the value of treating vitamin D not merely as a bone-health marker but as a potential modulator of surgical recovery. Anaesthesiologists and pain specialists in particular may find the opioid consumption data compelling, given the ongoing clinical and public health imperative to reduce unnecessary opioid use.

For researchers, the study's authors have effectively outlined the next study that needs to be done: a randomised controlled trial in which vitamin D-deficient breast cancer patients are assigned to supplementation or placebo before surgery, with post-operative pain and opioid consumption as primary outcomes. Until that trial exists, the association observed here — while solid and biologically plausible — remains an association rather than a proven causal relationship.

The broader lesson applies across nutritional medicine: micronutrient status at the time of a major physiological stressor like surgery can shape recovery in ways that standard pre-operative assessments may miss. Vitamin D, given its wide-ranging effects on inflammation, immune function, and neural signalling, is a particularly credible candidate for influencing that recovery. This study adds a specific, quantified data point to that argument — and gives clinicians a concrete threshold (30 nmol/L) and a concrete outcome (threefold higher odds of moderate-to-severe pain) to anchor the conversation.

For readers interested in related nutritional approaches to pain and inflammation, our coverage of natural supplements for knee arthritis pain and algae omega-3 DHA supplements explores other evidence-based options in the anti-inflammatory supplement space.